RESUMO
Enormous studies have corroborated that long non-coding RNAs (lncRNAs) extensively participate in crucial physiological processes such as metabolism and immunity, and are closely related to the occurrence and development of tumors, cardiovascular diseases, nervous system disorders, nephropathy, and other diseases. The application of lncRNAs as biomarkers or intervention targets can provide new insights into the diagnosis and treatment of diseases. This paper has focused on the emerging research into lncRNAs as pharmacological targets and has reviewed the transition of lncRNAs from the role of disease coding to acting as drug candidates, including the current status and progress in preclinical research. Cutting-edge strategies for lncRNA modulation have been summarized, including the sources of lncRNA-related drugs, such as genetic technology and small-molecule compounds, and related delivery methods. The current progress of clinical trials of lncRNA-targeting drugs is also discussed. This information will form a latest updated reference for research and development of lncRNA-based drugs.
RESUMO
Mitochondrial transcription has been studied as a function of mitochondriogenesis in yeast cells. Two systems have been used: synchronously growing cells and cells subjected to glucose repression followed by derepression. Maximal RNA synthesis has been found in the S phase of the cell cycle and during the 'repressed' phase in asynchronous cells. Activities of RNA polymerase, poly A polymerase and incorporation of [32P]-into RNA in vitro are maximal at the same period. Gel analysis reveals the presence of some high molecular weight RNA species which are likely to be precursors. When chase experiments are carried out in the presence of excess glucose, the high molecular weight species remain unaffected, suggesting that RNA processing may be an important site of action of glucose repression.